Compare BBWI & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBWI | LIVN |
|---|---|---|
| Founded | 1963 | 1987 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.5B |
| IPO Year | 1994 | 2015 |
| Metric | BBWI | LIVN |
|---|---|---|
| Price | $17.87 | $64.95 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 15 | 7 |
| Target Price | $24.88 | ★ $72.43 |
| AVG Volume (30 Days) | ★ 5.6M | 678.6K |
| Earning Date | 05-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.46% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.11 | N/A |
| Revenue | ★ $7,291,000,000.00 | N/A |
| Revenue This Year | N/A | $9.79 |
| Revenue Next Year | $2.19 | $6.89 |
| P/E Ratio | $5.76 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $14.28 | $34.24 |
| 52 Week High | $34.29 | $71.58 |
| Indicator | BBWI | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | 40.60 | 54.81 |
| Support Level | $16.72 | $61.60 |
| Resistance Level | $19.89 | $65.61 |
| Average True Range (ATR) | 0.92 | 2.02 |
| MACD | 0.10 | 0.31 |
| Stochastic Oscillator | 42.99 | 73.86 |
Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with just 4% of sales from international markets in fiscal 2025. For fiscal 2025, 77% of sales stemmed from the brick-and-mortar network (which was composed of more than 1,900 retail stores), similar to 2024 levels, as consumer shopping patterns remained normal. Future growth is expected from store upgrades, digital and international channels, as well as adjacent category expansions like men's and lip.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.